Glycine-assisted enhancement of 1,4-β-d-xylan xylanohydrolase activity at alkaline pH with a pH optimum shift

2007 ◽  
Vol 388 (1) ◽  
pp. 61-65 ◽  
Author(s):  
Vinod Vathipadiekal ◽  
Anamika Verma ◽  
Mala Rao

Abstract This is the first report describing the enhancement of xylanase activity by the neutral amino acid glycine. Xylanase activity is increased seven-fold at alkaline pH in the presence of glycine and its pH optimum is shifted from pH 7 to 8 without using any protein engineering techniques. Analysis of the steady-state kinetics revealed that glycine in the reaction mixture increases the K m and k cat values of the enzyme. Chemoaffinity labeling and studies using glycine esters indicate an involvement of the carboxylate ion of glycine in enhancing xylanase catalytic activity. A novel possible mechanism for the glycine-assisted catalytic action of xylanase is proposed.

Biochemistry ◽  
2007 ◽  
Vol 46 (12) ◽  
pp. 3872-3880 ◽  
Author(s):  
Zhou Zhang ◽  
George Papageorgiou ◽  
John E. T. Corrie ◽  
Christof Grewer

1972 ◽  
Vol 27 (9) ◽  
pp. 1054-1055 ◽  
Author(s):  
Judith G. Voet ◽  
David J. T. Porter ◽  
Harold J. Bright

We describe anaerobic stopped-flow monitored interactions of D-B-chloroalanine with D-amino acid oxidase and show that the kinetics of absorbance changes at 550 nm due to enzyme-bound intermediates can not be correlated with steady state turnover behavior unless it is assumed that only a small fraction of the enzyme directly participates in the α-β elimination process.


2018 ◽  
Vol 24 (2) ◽  
pp. 111-120 ◽  
Author(s):  
Sanjay J. Danthi ◽  
Beirong Liang ◽  
Oanh Smicker ◽  
Benjamin Coupland ◽  
Jill Gregory ◽  
...  

SLC6A19 (B0AT1) is a neutral amino acid transporter, the loss of function of which results in Hartnup disease. SLC6A19 is also believed to have an important role in amino acid homeostasis, diabetes, and weight control. A small-molecule inhibitor of human SLC6A19 (hSLC6A19) was identified using two functional cell-based assays: a fluorescence imaging plate reader (FLIPR) membrane potential (FMP) assay and a stable isotope-labeled neutral amino acid uptake assay. A diverse collection of 3440 pharmacologically active compounds from the Microsource Spectrum and Tocriscreen collections were tested at 10 µM in both assays using MDCK cells stably expressing hSLC6A19 and its obligatory subunit, TMEM27. Compounds that inhibited SLC6A19 activity in both assays were further confirmed for activity and selectivity and characterized for potency in functional assays against hSLC6A19 and related transporters. A single compound, cinromide, was found to robustly, selectively, and reproducibly inhibit SLC6A19 in all functional assays. Structurally related analogs of cinromide were tested to demonstrate structure–activity relationship (SAR). The assays described here are suitable for carrying out high-throughput screening campaigns to identify modulators of SLC6A19.


Sign in / Sign up

Export Citation Format

Share Document